tbuckley/cabot-search huggingface dataset:
Evaluation of the quality of psychiatric care for the aged
Authors: C Eisdorfer
Journal: American Journal of Psychiatry (1977)

Older persons represent a high proportion of those receiving care in institutions because of behavioral problems; relatively few aged people are treated in mental health center and other outpatient settings. The author believes that the availability and accessibility of community services should be among the most important variables used in assessing quality of care for the aged. He encourages the establishment of new norms for the quality of services needed to restore and maintain maximum physical, psychological, and social integrity.
The B7-H3 Protein In Acute Myeloid Leukemia
Authors: Thomas Guéry, Christophe Roumier, Céline Berthon, Pascale Lepelley, Aline Renneville, Olivier Nibourel, Florent Dumezy, Valérie Soenen, Catherine Roche, Claude Preudhomme, Bruno Quesnel
Journal: Blood (2013)
Human Interferon as a Therapeutic Agent
Authors: Thomas C. Merigan
Journal: New England Journal of Medicine (1988)

The therapeutic potential of interferon has been reviewed twice before in these columns.1 , 2 After an initial period of limited availability of the natural material, followed by a period of unrealistic expectations when cloning made interferon readily available, the real usefulness of interferon is just beginning to be understood. Last year, the U.S. Food and Drug Administration licensed two firms to sell recombinant interferon alfa for the treatment of hairy-cell leukemia. Its local administration in condylomata acuminata is the application most likely to be licensed next in the United States.Why is there such a limited series of uses despite interferon's . . .
AB0242 Rheumatoid Arthritis Patient's Opinion When Being in Remission: Why Many Patients Classify their Disease Activity as “Good” but not “Excellent”
Authors: B. Rintelen, J. Sautner, A. Leeb, A. König, N. Fritzer, C. Zieger, H.-P. Brezinschek, B. Leeb
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Objectives</h3> Remission is the goal in treating RA patients. In a chronic disease like rheumatoid arthritis (RA), the patient9s perspective may differ from the opinion of the treating physician. We ask our patients to rate their satisfaction with disease activity as such on a numerical scale from 1 “excellent” to 5 “failed” (PATSAT). In 3130 consecutive assessments, 529 in 247 pats fulfilled remission criteria according to DAS28 as well as to RADAI-5, a patient related outcome. 63% indicated PATSAT “excellent”, 35% “good” and 2% worse than that. It was of interest to investigate, why one third of these patients rated in a different way, as expected. <h3>Methods</h3> Remission was defined as a DAS28-ESR ≤2.6 <i>and</i> a RADAI-5 ≤1.4 to obtain a clinical as well as a patient related outcome defining disease activity. 44 consecutive RA patients in remission classifying their PATSAT as 1 or 2 where asked for their reason to rate this way. Patients9 clinical aspects were related to PATSAT 1 and 2. We had a closer look at the last two assessments of these patients to obtain information if disease course influences the decision. Moreover, three clinical psychologists categorized the obtained answers based on anxiety and/or depression. We present the differences in the two groups. <h3>Results</h3> Twelve patients rated PATSAT 1 and 32 PATSAT 2. Patients did not differ in age, gender, disease duration or RA-therapy. We observed two different types of answers: First, patients with PATSAT 1 do not mention any clinical aspects of RA except pain, whereas this is the case in 91.3% of the patients with PATSAT 2. Moreover, pain seems to be important for scoring different: If pain is part of the answers of patients with PATSAT 1 (in 25%), there is definitely no pain at all, whereas in one third of the answers of patients with PATSAT 2 pain is the cause to rate this way. There also seems to be a more anxious and depressive attitude to the disease course when ranking PATSAT 2 and not PATSAT 1. Patients with PATSAT 1 had a lower CDAI, SDAI, RADAI-5, HAQ-DI, VASpain and VASGH than patients with PATSAT 2. More patients with PATSAT 1 were in Boolean Remission. Disease course in the past shows more disease activity and higher HAQs in patients with PATSAT 2 than with PATSAT 1. <h3>Conclusions</h3> Pain and a higher level of anxiety/fear of worsening as well as a more unfortunate disease course may be the main reasons for patients to classify remission in RA as a state of “good” but not “excellent”. <h3>Disclosure of Interest</h3> None declared
Use and Interpretation of a Rapid Respiratory Syncytial Virus Antigen Detection Test Among Infants Hospitalized in a Neonatal Intensive Care Unit — Wisconsin, March 2015
Authors: Lina I. Elbadawi, Thomas Haupt, Erik Reisdorf, Tonya Danz, Jeffrey P. Davis
Journal: MMWR Morbidity and Mortality Weekly Report (2015)

On March 25, 2015, the Wisconsin Division of Public Health was notified of a possible respiratory syncytial virus (RSV) infection outbreak among infants hospitalized in a neonatal intensive care unit (NICU). On March 23, the index patient (neonate A), aged 3 days, had feeding intolerance and apnea. A nasopharyngeal swab specimen collected from neonate A was tested using a single-manufacturer rapid RSV antigen detection test (RRADT) at the hospital laboratory; the result was positive. The following day, because of concern about the possibility of more widespread RSV infection, RRADT was used to test nasopharyngeal swab specimens from neonate B, aged 1 month, who had resided in a different hospital room in the NICU and had developed an increased oxygen requirement, apnea, and poor feeding that day, as well as from two asymptomatic neonates who were hospitalized in the same room with neonate A; all three were positive. Later that day, nasopharyngeal swab specimens from the remaining 16 asymptomatic NICU patients were tested using the same RRADT; seven tests were positive, making a total of 11 positives. All 20 RRADTs were performed at the hospital laboratory.
POR Relations
Authors: Francis A. Neelon
Journal: New England Journal of Medicine (1974)

There are, as Wallace Stevens reminded us, 13 ways of looking at a blackbird. But until the report by Fletcher, in this issue of the Journal, there has been only one way of analyzing the effectiveness of medical records — an analysis based on certain axiomatic and "self-evident" principles of medical practice. Thus Weed1 and Hurst2 and others have proposed that clinicians should keep problem-oriented records (POR) because such records ought to aid in the process of caring for patients. If one accepts the goals, then use of the POR is alleged to follow as a "logical" consequence. We . . .
Localization <italic>In Vivo</italic> of Radioiodinated Anti-Rat-Fibrin Antibodies and Radioiodinated Rat Fibrinogen in the Murphy Rat Lymphosarcoma and in Other Transplantable Rat Tumors<xref ref-type="fn" rid="FN1">2</xref>
Authors: Eugene D. Day, Jakob A. Planinsek, David Pressman
Journal: JNCI Journal of the National Cancer Institute (1959)

Radioiodinated rabbit-anti-rat-fibrin antibodies purified by absorption and elution from rat fibrin localized in vivo, in the solid form of the Murphy rat lymphosarcoma and in three other transplantable rat tumors, like the anti-ascites-tumor antibodies purified from ascites tumor sediment. Radioiodinated rat and human fibrinogens also localized in a like manner in the lymphosarcoma but not always to the same extent. Several other antiserums, including those prepared against solid and ascites forms of the Murphy-Sturm lymphosarcoma, against ascites forms of three other rat tumors, and against human fibrinogen, contained antibodies with a cross reaction to rat fibrin, which localized in the Murphy lymphosarcoma when purified from rat fibrin. It is suggested that the type of antibody localization described was mediated through fibrinogen during its conversion to fibrin in the tumor mass. The antibody combined with fibrinogen in the circulation and was fixed with it in the tumor.
PTU-079 Non-invasive testing is diagnostic and prognostic in intestinal graft versus host disease
Authors: B Hayee, P Pavlidis, L Floro, V Potter, G Mufti
Journal: Gut (2015)

<h3>Introduction</h3> Intestinal graft versus host disease (iGVHD) is a debilitating and sometimes fatal consequence of bone marrow transplantation<sup>1</sup>. Malnutrition and profuse diarrhoea are common. The diagnosis is often based on clinical criteria alone and intestinal biopsies are frequently negative.<sup>1,2</sup>Even after successful treatment, iGVHD can relapse and reliable disease monitoring is unavailable. We conducted this prospective study to evaluate the diagnostic accuracy of the xylose/rhamnose/lactulose small bowel permeability test (SBPT) and faecal calprotectin (FC) in the work-up of patients with suspected iGVHD. <h3>Method</h3> Prospective data was collected on all patients referred for endoscopic investigation of suspected iGVHD at KCH, from Jan–Dec 2014. All patients underwent OGD and colonoscopy to at least the caecum, with serial intestinal biopsies taken. Samples were collected for SBPT and FC. Infection and other pathologies were excluded with extensive testing. SBPT and FC results were compared to biopsy results. <h3>Results</h3> 15 patients had positive intestinal biopsies (PB) with 9 negative (NB). SBPT was unavailable in 2, and FC in 1 patient in each group. SBPT was abnormal in 1/7 NB and in 11/13 PB. The sensitivity (Sn) and specificity (Sp) for SBPT in the diagnosis of iGVHD was 84.6% and 85.7% respectively; PPV 91.7%. FC was high in 2/8 NB and 9/14 PB, returning Sn 64.2% and Sp 75%. Addition of the two tests reduced sensitivity and specificity further. Mortality was high in the PB group (6/14, 43% – exclusively from gram-negative sepsis +/- multi-organ failure). FC was elevated &gt;300 mcg/g in 5/6 deaths and 2/8 survivors. <h3>Conclusion</h3> SBPT appears to be a highly sensitive and specific marker of iGVHD. A high FC does not appear to be related to iGVHD itself, but may predict severe disease and mortality. These non-invasive tests are simple and cheap and may serve to assist clinicians in the investigation and management of this debilitating condition. <h3>Disclosure of interest</h3> None Declared. <h3>References</h3> Ferrara JL, <i>et al</i>. Lancet 2009;373:1550–1561 Ross WA, Couriel D. <i>Curr Opin Gastroenterol</i>. 2005;<b>21</b>:64–69
Amnion Implantation in Peripheral Vascular Disease
Authors: W B WELPLY
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medication Sharing, Storage, and Disposal Practices for Opioid Medications Among US Adults
Authors: Alene Kennedy-Hendricks, Andrea Gielen, Eileen McDonald, Emma E. McGinty, Wendy Shields, Colleen L. Barry
Journal: JAMA Internal Medicine (2016)

the web-based panel survey mode reduces this concern.Although respondents were sampled from a nationally representative panel, there is no census of adults with past-year opioid medication use; therefore, we cannot verify that this study sample is representative of US adults with recent opioid medication use.More research is needed to identify effective strategies to advance safer practices related to opioid medication sharing, storage, and disposal. 6In the meantime, reducing the prescribing of large quantities of opioid medications and disseminating clear recommendations on safe storage and disposal of opioid medications widely to the public and prescribers may reduce risks.
Length Polymorphisms in Heme Oxygenase-1 and AKI after Cardiac Surgery
Authors: David E. Leaf, Simon C. Body, Jochen D. Muehlschlegel, Gearoid M. McMahon, Peter Lichtner, Charles D. Collard, Stanton K. Shernan, Amanda A. Fox, Sushrut S. Waikar
Journal: Journal of the American Society of Nephrology (2016)

Heme oxygenase-1 (HO-1) catalyzes the degradation of heme, which may be involved in the pathogenesis of AKI. Length polymorphisms in the number of GT dinucleotide repeats in the HO-1 gene ( HMOX1 ) promoter inversely associate with HMOX1 mRNA expression. We analyzed the association between allelic frequencies of GT repeats in the HMOX1 gene promoter and postoperative AKI in 2377 white patients who underwent cardiac surgery with cardiopulmonary bypass. We categorized patients as having the short allele (S; &lt;27 GT repeats) or long allele (L; ≥27 GT repeats), and defined AKI as an increase in serum creatinine ≥0.3 mg/dl within 48 hours or ≥50% within 5 days, or the need for RRT. Compared with patients with the SS genotype, patients with the LL genotype had 1.58-fold (95% confidence interval, 1.06 to 2.34; P =0.02) higher odds of AKI. After adjusting for baseline and operative characteristics, the odds ratio for AKI per L allele was 1.26 (95% confidence interval, 1.05 to 1.50; P =0.01). In conclusion, longer GT repeats in the HMOX1 gene promoter associate with increased risk of AKI after cardiac surgery, consistent with heme toxicity as a pathogenic feature of cardiac surgery-associated AKI, and with HO-1 as a potential therapeutic target.
FRI0222 Impact of a Multidisciplinary Approach in Enteropathic Spondiloarthritis: Usefulness of a Combined Assessment in Prevalence, Characteristics, Diagnostic Delay and Outcomes
Authors: M.S. Chimenti, P. Conigliaro, M. Ascolani, E. Ballanti, S. Onali, P. Triggianese, G. Collalti, E. Calabrese, C. Petruzziello, F. Pallone, L. Biancone, R. Perricone
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Prevalence of Enteropathic-related Spondyloarthritis (SpAe) in inflammatory bowel disease (IBD) shows marked variations (18-45%) and may be underestimated by gastroenterologists. <h3>Objectives</h3> In a prospective study, in a combined GastroIntestinal and RHeumAtologic "GiRha" clinic of the University of Rome "Tor Vergata", prevalence and characteristics of joint manifestations in inflammatory bowel disease (IBD) patients were evaluated. diagnostic delay and therapeutic modifications were also assessed. <h3>Methods</h3> The study prospectively enrolled patients affected by IBD who presented muscolo-skeletal pain between November 2012 and July 2014. Disease activity in SpA patients was assessed using the ASDAS-CRP, BASDAI, BASFI, DAS44-CRP and HAQ-S. <h3>Results</h3> SpAe was detected in 101 patients. In 65 cases this was a new diagnosis. Other rheumatologic diagnosis were: Osteoarthritis (30.3%), Fybromialgia (6.9%), Psoriatic Arthritis (4.3%), Rheumatoid Arthritis (3.2%) and Gout (1.6%). Prevalence of other extraintestinal manifestations (psoriasis, uveitis, primary sclerosing cholangitis and erythema nodosum) resulted higher in SpAe patients than that in IBD non-SpAe patients (p=0.04). 56.4% SpAe patients showed a high disease activity (ASDAS ≥2.1). 22.8% had axial involvement, peripheral involvement in 57.4% and a combination of peripheral and axial involvement in 19.8% of cases. Axial SpAe patients were preferentially male and showed increased ESR and CRP levels compared with peripheral SpAe patients. Peripheral SpAe patients showed higher DAS levels compared with that in both axial and axial+peripheral SpAe patients. The diagnostic delay (time between the onset of joint symptoms and first rheumatological encounter) was calculated for all SpAe patients. Patients with disease onset between 2000-2009 had a reduced diagnostic delay compared with those with joint onset in 1980-1989 and 1990-1999. The diagnostic delay was further reduced for those patients with joint onset after 2010 (Figure 1). A higher percentage of IBD patients were treated with disease-modifying anti-rheumatic drugs (p=0.04), anti-COX2 (p&lt;0.0001) and anti-TNF drugs (p=0.001) after the rheumatological assessment. Clinical outcome demonstrate improuvement of disease activity after 6 months of combined aproach: ASDAS and DAS changed from 2.8±0.9 at baseline to 1.4±0.5 and 2.5±0.8 at baseline to 1.8±0.8 respectively. <h3>Conclusions</h3> Multidisciplinary care facilitates the diagnosis and the management of rheumatic disorders in IBD offering a comprehensive treatment approach. <h3>Disclosure of Interest</h3> None declared
PTU-084 Long term outcomes after transition to adult services in paediatric-onset inflammatory bowel disease patients treated with anti-tnf
Authors: C Pollington, FL Cameron, NA Kennedy, I Arnott, J Satsangi, DC Wilson
Journal: Gut (2015)

<h3>Introduction</h3> Anti-TNF therapy use in paediatric IBD (PIBD) is increasing worldwide with evidence of short-term effectiveness and safety. Longer term outcomes are less clear due to lack of follow-up (FU) of young people after transition to adult services. We aimed to assess effectiveness and safety of anti-TNF therapy in PIBD post-transition to adult care. <h3>Method</h3> A retrospective case review of PIBD patients treated with anti-TNF (Infliximab (IFX) or Adalimumab (ADA)) in the SE Scotland regional PIBD unit at RHSC, Edinburgh and then transitioned to the regional adult specialist IBD centre at WGH, Edinburgh, during 01/01/00–30/09/13. Data (including outcome and duration of anti-TNF therapy, dose escalation, adverse events and discontinuation/re-start of therapy) were collected prior to, at the time of transition from PIBD services, and to study end point (transfer out of region, loss to FU, death or ongoing adult care at 31/07/2014), a minimum 10 months FU. <h3>Results</h3> 34 children (30 Crohn’s disease (CD), 4 ulcerative colitis (UC)) had anti-TNF exposure in PIBD services then a median (range) duration of FU post-transition of 2.9 (0.7–9.3) years. At transition, 19/34 were still on anti-TNF (12 IFX and 7 ADA). 10/12 IFX were in steroid-free remission (SFR) and 8/10 remained in SFR at last FU; 2 discontinued IFX due to loss of response (LoR), both then had ADA with 1 ADA LoR and 1 SFR on ADA at last FU. 1/12 IFX patient with moderate disease at transition then achieved remission, had planned drug withdrawal (PDW) then relapsed, restarted IFX and had mild disease at last FU. 1/12 IFX patients had response with mild disease post-induction IFX but transitioned and had primary non-response (PNR) by 6 doses IFX, and switched to ADA with moderate disease activity at last FU. 3/7 ADA patients at transition were in SFR; 1 stopped as PDW in prolonged remission but 2 stopped due to adverse events. 2/7 ADA patients with mild disease at transition then achieved sustained remission up to last FU. 2/7 ADA patients had moderate disease at transition; one had ADA LoR and moderate disease at last FU, the other gained remission so had PDW, relapsed but was in remission at last FU. There were no deaths or malignancies associated with anti-TNF use. <h3>Conclusion</h3> Anti-TNF therapy post-transition is effective at maintaining remission in those with remission prior to transition, although some may require a 2nd anti-TNF agent to maintain remission. Those previously not in remission can achieve sustained remission, usually if just starting anti-TNF maintenance at transition; others do not and have a more complicated disease course. Loss of response remains a key reason for stopping anti-TNF therapy. <h3>Disclosure of interest</h3> None Declared.
Bacterial biofilm in acute lesions of hidradenitis suppurativa
Authors: G.A. Okoye, N. Vlassova, O. Olowoyeye, A. Agostinho, G. James, P.S. Stewart, S. Leung, G. Lazarus
Journal: British Journal of Dermatology (2016)

Hidradenitis Suppurativa (HS) is a chronic inflammatory disorder of the hair follicles, characterized by recurrent tender subcutaneous nodules, sinus tracts, and scarring in regions of the body with a high density of apocrine glands. Studies on the epidemiology of HS have shown a range of prevalences between 0.053 and 4%.1 The female:male ratio of HS is approximately 3:1,2 and HS may be more common in people of African descent.3-5

This article is protected by copyright. All rights reserved.
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
Authors: Jeffrey S Weber, Geoff Gibney, Ryan J Sullivan, Jeffrey A Sosman, Craig L Slingluff, Donald P Lawrence, Theodore F Logan, Lynn M Schuchter, Suresh Nair, Leslie Fecher, Elizabeth I Buchbinder, Elmer Berghorn, Mary Ruisi, George Kong, Joel Jiang, Christine Horak, F Stephen Hodi
Journal: The Lancet Oncology (2016)
P2-312: A retrospective study of salvage chemotherapy for advanced non-small cell lung cancer; the efficacy of third and fourth chemotherapy.
Authors: Yuichi Tambo, Kazuo Kasahara, Hideharu Kimura, Takashi Sone, Tomoyuki Araya, Shunichi Tamori, Masaki Fujimura, Shinji Nakao
Journal: Journal of Thoracic Oncology (2007)